A Phase II, Open-Label Trial, to Evaluate the Safety, Tolerability and Antiviral Activity of TMC125 in Antiretroviral Experienced HIV-1 Infected Children and Adolescents.

Trial Profile

A Phase II, Open-Label Trial, to Evaluate the Safety, Tolerability and Antiviral Activity of TMC125 in Antiretroviral Experienced HIV-1 Infected Children and Adolescents.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Etravirine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms PIANO
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Nov 2015 Final results published in the Antiviral Therapy.
    • 30 Jun 2012 Additional trial location added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top